La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Micro-X Croissance future

Future contrôle des critères 2/6

Micro-X is forecast to grow earnings and revenue by 61.1% and 35.5% per annum respectively. EPS is expected to grow by 80.3% per annum. Return on equity is forecast to be -37.2% in 3 years.

Informations clés

61.1%

Taux de croissance des bénéfices

80.3%

Taux de croissance du BPA

Medical Equipment croissance des bénéfices	16.0%
Taux de croissance des recettes	35.5%
Rendement futur des capitaux propres	-37.2%
Couverture par les analystes	Low
Dernière mise à jour	29 Jul 2024

Mises à jour récentes de la croissance future

Recent updates

Shareholders May Not Be So Generous With Micro-X Limited's (ASX:MX1) CEO Compensation And Here's Why

Nov 07

We Think Micro-X (ASX:MX1) Needs To Drive Business Growth Carefully

Jul 07

Here's Why We're Watching Micro-X's (ASX:MX1) Cash Burn Situation

Mar 01

What We Learned About Micro-X's (ASX:MX1) CEO Pay

Jan 29

What Kind Of Shareholders Hold The Majority In Micro-X Limited's (ASX:MX1) Shares?

Jan 08

Have Insiders Been Buying Micro-X Limited (ASX:MX1) Shares?

Dec 18

Micro-X Limited's (ASX:MX1) Shift From Loss To Profit

Nov 27

Prévisions de croissance des bénéfices et des revenus

ASX:MX1 - Estimations futures des analystes et données financières antérieures (AUD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2026	41	-2	N/A	-3	1
6/30/2025	31	-5	N/A	-4	1
6/30/2024	24	-10	N/A	-2	1
12/31/2023	15	-15	-5	-5	N/A
9/30/2023	15	-13	-9	-8	N/A
6/30/2023	15	-11	-12	-11	N/A
3/31/2023	15	-11	-14	-13	N/A
12/31/2022	15	-12	-15	-14	N/A
9/30/2022	12	-15	-17	-16	N/A
6/30/2022	9	-17	-19	-18	N/A
3/31/2022	6	-18	-18	-16	N/A
12/31/2021	4	-19	-16	-15	N/A
9/30/2021	4	-17	-13	-12	N/A
6/30/2021	4	-15	-11	-10	N/A
3/31/2021	5	-13	-12	-11	N/A
12/31/2020	6	-11	-13	-12	N/A
9/30/2020	5	-10	-12	-11	N/A
6/30/2020	4	-10	-12	-9	N/A
3/31/2020	3	-9	-11	-8	N/A
12/31/2019	2	-8	-10	-7	N/A
9/30/2019	2	-9	-9	-7	N/A
6/30/2019	2	-10	-9	-7	N/A
3/31/2019	2	-14	-9	-8	N/A
12/31/2018	2	-18	-10	-9	N/A
9/30/2018	2	-17	-9	-8	N/A
6/30/2018	2	-17	-8	-8	N/A
3/31/2018	1	-14	-10	-9	N/A
12/31/2017	1	-11	-11	-11	N/A
9/30/2017	1	-12	N/A	-11	N/A
6/30/2017	1	-13	N/A	-11	N/A
3/31/2017	1	-13	N/A	-10	N/A
12/31/2016	1	-13	N/A	-9	N/A
9/30/2016	1	-12	N/A	-11	N/A
6/30/2016	1	-11	N/A	-13	N/A
3/31/2016	1	-12	N/A	-10	N/A
12/31/2015	0	-13	N/A	-8	N/A
9/30/2015	0	-11	N/A	-7	N/A
6/30/2015	0	-10	N/A	-6	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MX1 is forecast to remain unprofitable over the next 3 years.

Bénéfices vs marché: MX1 is forecast to remain unprofitable over the next 3 years.

Croissance élevée des bénéfices: MX1 is forecast to remain unprofitable over the next 3 years.

Chiffre d'affaires vs marché: MX1's revenue (35.5% per year) is forecast to grow faster than the Australian market (5.4% per year).

Croissance élevée des revenus: MX1's revenue (35.5% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: MX1 is forecast to be unprofitable in 3 years.

Micro-X Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Consensus revenue estimates fall by 20%

Price target decreased by 11% to AU$0.25

Forecast breakeven date pushed back to 2025

Consensus forecasts updated

Price target decreased to AU$0.36

Price target decreased to AU$0.51

Recent updates

Take Care Before Diving Into The Deep End On Micro-X Limited (ASX:MX1)

Micro-X Limited has completed a Follow-on Equity Offering in the amount of AUD 3.9 million.

New minor risk - Shareholder dilution

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 4 million.

Micro-X Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.

New minor risk - Share price stability

Micro-X Limited (ASX:MX1) Doing What It Can To Lift Shares

Micro-X Reveals First Look At New Mobile Stroke Diagnosis Device

Consensus revenue estimates fall by 20%

Price target decreased by 11% to AU$0.25

New minor risk - Profitability

Micro-X Limited, Annual General Meeting, Nov 16, 2023

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Financial data availability

Non-Executive Director exercised options to buy AU$174k worth of stock.

Sentiment Still Eluding Micro-X Limited (ASX:MX1)

Forecast breakeven date pushed back to 2025

Is Micro-X (ASX:MX1) In A Good Position To Invest In Growth?

First half 2023 earnings released: AU$0.008 loss per share (vs AU$0.019 loss in 1H 2022)

Less than half of directors are independent

Micro-X Limited announced that it has received AUD 7.454223 million in funding from Varex Imaging Corporation

Less than half of directors are independent

Shareholders May Not Be So Generous With Micro-X Limited's (ASX:MX1) CEO Compensation And Here's Why

Consensus forecasts updated

Less than half of directors are independent

Micro-X Limited, Annual General Meeting, Nov 14, 2022

Micro-X Limited Announces Resignation of Yasmin King as Director

Micro-X Limited announced that it expects to receive AUD 7.454223 million in funding from Varex Imaging Corporation

Micro-X Limited Launches Next Generation Micro-X Rover, the Rover Plus

Full year 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to AU$0.36

We Think Micro-X (ASX:MX1) Needs To Drive Business Growth Carefully

Price target decreased to AU$0.51

Micro-X Ltd Appoints Ilona Meyer to Its Board as A Non-Executive Director and Member of the Micro-X Audit & Risk Committee, Effective 7Th March 2022

Here's Why We're Watching Micro-X's (ASX:MX1) Cash Burn Situation

Consensus forecasts updated

Consensus revenue estimates fall by 34%

Full year 2021 earnings released: AU$0.037 loss per share (vs AU$0.043 loss in FY 2020)

Consensus revenue estimates fall to AU$4.20m

Micro-X Ltd Launches New Version of the Rover Mobile DR for Use in Small-Animal Veterinary Hospitals

Micro-X Limited Announces Rover FDA Approval Opens US Healthcare Market

Consensus forecasts updated

Analysts update estimates

First half 2021 earnings released: AU$0.013 loss per share (vs AU$0.025 loss in 1H 2020)

New 90-day high: AU$0.40

Micro-X Limited announced that it expects to receive AUD 30.5 million in funding

What We Learned About Micro-X's (ASX:MX1) CEO Pay

What Kind Of Shareholders Hold The Majority In Micro-X Limited's (ASX:MX1) Shares?

New 90-day high: AU$0.39

Micro-X Limited Signs $1.3 Million Rover Contract for Australian Defence Force

Have Insiders Been Buying Micro-X Limited (ASX:MX1) Shares?

Micro-X Limited Announces Rejoining of Jim McDowell as Non-Executive Director from January 1, 2021

New 90-day high: AU$0.36

Micro-X Limited's (ASX:MX1) Shift From Loss To Profit

Price target raised to AU$0.50

Micro-X Limited Amends Nano Distribution Agreement with Carestream Health Inc

Micro-X Ltd Announces Management Changes

New 90-day high: AU$0.26

Analysts update estimates

Micro-X Limited Signs $1.4 Million Contract for Rover Launches Micro-X Second Product

New 90-day high: AU$0.21

Micro-X Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.043 loss per share

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance